Pharmaceutical major Cadila Healthcare Ltd (Zydus Cadila) on Thursday reported a 40 per cent decline in the Group's consolidated net profit, although the company's standalone PAT rose by 27 per cent in the second quarter of 2011-12, ended September 30, compared to the corresponding period in the last fiscal year.
In a filing with the BSE, the company said the Group's consolidated unaudited sales were Rs 1,247.44 crore (Rs 1,120.54 crore), an increase of 11 per cent, while PAT stood at Rs 102.68 crore (Rs 170.84 crore), a decline of 40 per cent.
On a standalone basis, the company's sales were Rs 924.61 crore (Rs 762.71 crore), an increase of 21 per cent while PAT was Rs 230.98 crore (Rs 181.60 crore), up 27 per cent.
On Wednesday, Cadila Healthcare's share price at the BSE closed 1.02 per cent down at Rs 760.